ライフサイエンスコーパス: 5-lipoxygenase-activating protein

1 as serine proteinases, histamine 4-receptor, 5-lipoxygenase-activating protein, 15-lipoxygenase-1, pr

2 mic stroke: phosphodiesterase 4D (PDE4D) and 5-lipoxygenase activating protein (ALOX5AP).

3 Arachidonate 5-lipoxygenase-activating protein (ALOX5AP) is an arachi

4 genase (ALOX5) and its partner, arachidonate 5-lipoxygenase-activating protein (ALOX5AP), are involve

5 5-Lipoxygenase-activating protein, an arachidonate trans

6 in its consensus N-terminal two-thirds with 5-lipoxygenase-activating protein and has a region (resi

7 ing positive antibody binding to 5-LO, FLAP (5-lipoxygenase activating protein), and leukotriene A4 h

8 o-localizes with cPLA2alpha, 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 sy

9 enase (LO) activity and was inhibited by the 5-lipoxygenase-activating protein antagonist MK 886 and

10 diaI infarction, including ALOX5AP (encoding 5-lipoxygenase-activating protein) associated with myoca

11 to compensatory changes of 5-lipoxygenase or 5-lipoxygenase activating protein but rather an apparent

12 ave previously reported that exposure to the 5-lipoxygenase activating protein-directed inhibitor MK8

13 mology of its amino acid sequence to that of 5-lipoxygenase activating protein (FLAP) but none to tha

14 Although deletion of the 5-lipoxygenase activating protein (FLAP) did not influen

15 n of five AA metabolizing enzymes as well as 5-lipoxygenase activating protein (FLAP) in a panel of h

16 A drug discovery program in search of novel 5-lipoxygenase activating protein (FLAP) inhibitors focu

17 5-lipoxygenase activating protein (FLAP) is abundantly p

18 diovascular disease, and an inhibitor of the 5-lipoxygenase activating protein (FLAP) is in clinical

19 5-Lipoxygenase activating protein (FLAP) plays a critica

20 s showed hypoxia augmented the expression of 5-lipoxygenase activating protein (FLAP), a key enzyme i

21 e show that expression of 5-lipoxygenase and 5-lipoxygenase activating protein (FLAP), key catalytic

22 We examined expression of the 5-lipoxygenase activating protein (FLAP), which is criti

23 ists of multimers of LTC(4) synthase and the 5-lipoxygenase activating protein (FLAP).

24 derivative 11j has an IC(50) of 4.2 nM in a 5-lipoxygenase-activating protein (FLAP) binding assay,

25 Specific inhibitors of 5-lipoxygenase and 5-lipoxygenase-activating protein (FLAP) blocked airway

26 we report that DBA/1 mice made deficient in 5-lipoxygenase-activating protein (FLAP) by gene targeti

27 Inhibitors of 5-lipoxygenase-activating protein (FLAP) have been found

28 ed the mRNA expression of 5-lipoxygenase and 5-lipoxygenase-activating protein (FLAP) in human pulmon

29 n of a novel series of oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitors are

30 ipase A2 (cPLA2), 5-lipoxygenase (5-LO), and 5-lipoxygenase-activating protein (FLAP), but lacked LTC

31 y proteins, coactosin-like protein (CLP) and 5-lipoxygenase-activating protein (FLAP), can support 5L

32 ere it associates with its scaffold protein, 5-lipoxygenase-activating protein (FLAP), to form the co

33 al to those of the human genes for LTC4S and 5-lipoxygenase-activating protein (FLAP).

34 fraction and increased levels of lung tissue 5-lipoxygenase-activating protein (FLAP).

35 hydrophobic domain and carboxyl terminus of 5-lipoxygenase-activating protein for that of LTC4S.

36 4 (LTD4) receptor antagonist MK-571, and the 5-lipoxygenase activating protein inhibitor MK-886 all s

37 as performed using diethylcarbamazine or the 5-lipoxygenase activating-protein inhibitor MK-886.

38 ctions in this model were examined using the 5-lipoxygenase-activating protein inhibitor MK-886.

39 GSK2190915, a potent 5-lipoxygenase-activating protein inhibitor, prevents th

40 The 5-lipoxygenase-activating-protein inhibitor, MK-886, was

41 The potent and selective 5-lipoxygenase-activating protein leukotriene synthesis

42 reatment of neutrophils with an inhibitor of 5-lipoxygenase-activating protein (MK886) and thus synth

43 or cysLT synthesis by MK886, an inhibitor of 5-lipoxygenase-activating protein, reduced the response

44 5-Lipoxygenase-activating protein rescues activity of 5-

45 Human LTC4S and the 5-lipoxygenase-activating protein share substantial amin

46 lammation (cyclooxygenase 2, 5-lipoxygenase, 5-lipoxygenase-activating protein, tumor necrosis factor

47 tive protein and mRNA for 5-lipoxygenase and 5-lipoxygenase activating protein were present in cells

48 re centered on the integral membrane protein 5-Lipoxygenase-Activating Protein, which we identify as